For the quarter ended December 2024, Amedisys (AMED) reported income of $598.05 million, up 4.8% over the identical interval final yr. EPS got here in at $0.96, in comparison with $0.94 within the year-ago quarter.
The reported income represents a shock of -0.02% over the Zacks Consensus Estimate of $598.19 million. With the consensus EPS estimate being $1.05, the EPS shock was -8.57%.
Whereas buyers carefully watch year-over-year adjustments in headline numbers — income and earnings — and the way they evaluate to Wall Road expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
Since these metrics play a vital function in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps buyers higher venture a inventory’s value efficiency.
Right here is how Amedisys carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Internet Service Income- House well being: $377 million versus the three-analyst common estimate of $376.44 million. The reported quantity represents a year-over-year change of +5%.
- Internet Service Income- Hospice: $212.90 million versus the three-analyst common estimate of $213.11 million. The reported quantity represents a year-over-year change of +3.4%.
- Internet Service Income- Excessive Acuity Care: $8.10 million versus the two-analyst common estimate of $9.05 million. The reported quantity represents a year-over-year change of +37.3%.
View all Key Company Metrics for Amedisys here>>>
Shares of Amedisys have returned -1% over the previous month versus the Zacks S&P 500 composite’s -2.3% change. The inventory at present has a Zacks Rank #3 (Maintain), indicating that it may carry out consistent with the broader market within the close to time period.
Zacks’ Analysis Chief Names “Inventory Most More likely to Double”
Our workforce of consultants has simply launched the 5 shares with the best chance of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This high decide is among the many most progressive monetary corporations. With a fast-growing buyer base (already 50+ million) and a various set of innovative options, this inventory is poised for giant beneficial properties. In fact, all our elite picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Amedisys, Inc. (AMED) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
